Eli Lilly’s orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions and easier manufacturing.
Recent Posts
- Global week ahead: Trump’s Nobel dreams meet economic reality
- How the U.S. space industry became dependent on SpaceX
- Solar executives warn that Trump attack on renewables will lead to power crunch that spikes electricity prices
- Eli Lilly’s obesity pill remains a viable rival to Novo’s oral Wegovy despite data that underwhelmed investors
- This retirement plan feature offers tax-free growth — but only 18% of investors use it